Contact webmaster
Contact Clinical Trials Network
The Clinical Trials Network


  Mission
  General information
  Active trials
  Therapeutic groups
  Clinical site support
  NYP & Affiliates
  Training
  Map of the Network
  Trial summaries
 

Trial Summaries

Recruitment Ends in ADOPT; Follow-up until 2006


Study Purpose:

ADOPT (A Diabetes Outcome Progression Trial) is a randomized, double-blind study to compare the durability of glucose lowering and the preservation of pancreatic beta-cell function of rosiglitazone monotherapy with metformin or glyburide/glibenclamide in patients with drug-naïve, recently-diagnosed type 2 diabetes mellitus.

ADOPT is testing the hypothesis that rosiglitazone preserves pancreatic beta-cell function better than other drugs used as first line therapy for type 2 diabetes mellitus, thus delaying or preventing deterioration in glycemic control. Pancreatic beta-cell function will be assessed by an oral glucose tolerance test.

Rosiglitazone is an insulin-sensitizing drug, a new class of drugs that help insulin to work better in patients with type 2 diabetes. Because of it insulin-sensitizing action, rosiglitazone may preserve pancreatic beta-cell function better than other first line drugs for type 2 diabetes mellitus.

Study Design:

Patients recently diagnosed (<2 years) with type 2 diabetes who were eligible and had no exclusions were asked to participate in ADOPT. A 4-week trial of diet/exercise was utilized to identify those patients who remain insufficiently controlled (FPG >=126mg/dL and <=180mg/dL [7-10 mmol/L]). Such patients were eligible to be randomized to one of three treatments: (1) rosiglitazone, (2) glyburide or glibenclamide, or (3) metformin. Treatment was double-blind and lasted for approximately four years or until monotherapy failure, i.e., when fasting plasma glucose was confirmed to be >180 mg/dL.

Study Subjects and Recruitment:

Men and women, aged 30-75 years with type 2 diabetes mellitus diagnosed <two years before screening and managed without drug therapy were eligible for further screening.  Patients who had fasting plasma glucose values between 126 and 240 mg/dL were eligible for a four-week run-in with life-style interventions (diet and exercise).  At the end of the run-in, participants who had fasting plasma glucose values between 126 and 180 mg/dL were eligible for randomization to one of the three drug limbs.  About 300 centers in North America and Europe participated In ADOPT with each trying to recruit 12 patients for a total of 3,600 patients.  To account for dropout rates, the recruitment numbers were increased to 4,182. Recruitment closed on June 28, 2002 with 4,380 randomized worldwide.  The Columbia-Cornell Clinical Trials Network did an outstanding job recruiting for ADOPT.  Five clinical sites in our network participated: Columbia University Health Sciences, Albert Einstein College of Medicine/Jacobi Hospital, Cooper Health Care System, Diabetes Care and Information Center of New York, and Cornell Internal Medicine Associates.  Together our five sites randomized 132 participants, more than twice their collective goal of 60 participants.  Columbia University Health Sciences and Albert Einstein/Jacobi Hospital ranked first and second worldwide in terms of recruitment with 45 and 39 participants, respectively.

Follow-up

Follow-up in ADOPT is expected to continue until about June 2006.

 

 

 

Copyright © 1997-2009 Columbia University Medical Center